Please login to the form below
Troxyca ER
This page shows the latest Troxyca ER news and features for those working in and with pharma, biotech and healthcare.
FDA panel backs Pfizer and Teva abuse-resistant painkillers
In the case of Troxyca ER, the inclusion of opioid blocker naltrexone is designed to achieve the same end result. ... The company secured rights to Troxyca ER (also known as ALO-02) when it acquired King Pharmaceuticals in 2010 for $3.6bn.
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
Subscribe to our email news alerts
- Planting the Seeds for Future Women Leaders in Medicine
- FDA approves SpringWork’s Ogsiveo as first therapy for desmoid tumours
- GSK shares positive phase 3 results for Blenrep combination in multiple myeloma
- Stem cell therapy trial shows promising results for treating progressive MS
- Cancer Research UK calls on government to create ten-year cancer plan
- Risk calculator to prevent heart attacks and strokes in type 2 diabetes patients
No results were found
PMHub
Genesis Research Group
Genesis Research Group provides life science companies with a better way to develop impactful evidence and optimize market access by...
Latest intelligence
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
- The rise of digital healthcare – fuelled by open innovation in healthtech hubs
- How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...
